Novinky z výzkumu peptidů / live registry feed

Self-reactive human CD8⁺ T cells restricted by HLA-E mediate immunoregulatory and antiviral functions

HLA-E constitutively presents self VL9 peptides on healthy cells, signaling an intact HLA class I pathway and protecting cells from natural killer cell attack. Beyond this canonical role, HLA-E-restricted CD8 T cells that recognize foreign pathogen peptides have emerged as med…

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive stan…

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irra…

Nutraceutical Supplementation Combined With Physiotherapy for Rotator Cuff Tendinopathy

Rotator cuff tendinopathy is a common cause of shoulder pain and functional impairment. Exercise-based physiotherapy represents a cornerstone of conservative treatment, while nutraceutical supplementation has been proposed as a potential adjunctive strategy. This prospective, …

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or m…

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

This trial proposes to evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal infusion of a chemokine modulatory (CKM) regimen composed of a…

Study of G-CSF for DOR in Patients Undergoing IVF

Diminished ovarian reserve (DOR) is defined by reduced follicle counts in women, associated with decreased fertility and lower success rates with In Vitro Fertilization (IVF). Granulocyte Colony Stimulating Factor (G-CSF) is a medication that has been proposed as a potential t…

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

The goal of this clinical trial is to learn if a new trientine tetrahydrochloride (TETA 4HCl) formulation administered once a day compared to d-Penicillamine (DPA) as a first line treatment for people living with Wilson's disease (WD) is effective and safe. The study is enroll…

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer

Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)

Primary Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by mutations in genes encoded by nuclear Deoxyribonucleic Acid (DNA) or by mutations and/or deletions in the mitochondrial DNA (mtDNA). While some mitochondrial disorders on…

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed S…

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

This phase II trial compares the effect of amivantamab and hyaluronidase to cetuximab for the treatment of skin (cutaneous) squamous cell carcinoma that has come back after a period of improvement and has not spread to other parts of the body (locally recurrent) or that has sp…

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by …

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with…

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev)…

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with QL1706) in combination with pemetrexed in patients with leptomeningeal metastasis.

The DENOCHARCOT Trial

The aim of the present trial is to assess the efficacy of treatment of acute Charcot foot in diabetes patients with Prolia® on clinical relevant Outcomes in a randomized, double blind, placebo-controlled trial.

STunning in Acute Myocardial Infarction - BAS

The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with…

Study of COYA 302 for the Treatment of ALS

The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS). COYA 302 is an investigational and proprietary biologic c…

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-g…

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

This early phase I trial evaluates different administration techniques (oral or intravenous) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it first started (primary site) to the br…

A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control

This study will evaluate whether VCT220 tablets improve blood glucose control in adults with type 2 diabetes whose blood glucose remains inadequately controlled with lifestyle intervention alone, metformin alone, or metformin combined with a sodium-glucose cotransporter 2 (SGL…

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

This is a Phase 1/2, randomized, controlled, open-label, proof-of-concept study to evaluate the safety and tolerability, local and systemic PK profiles of TNP-2092 administered via IA injection on the basis of vancomycin IV and oral antibiotics therapy in participants with ear…

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic the…

Emulation of the SUNLIGHT Trial Using Specialty Oncology Electronic Health Records Databases

This observational study uses existing U.S. specialty oncology electronic health records to emulate the SUNLIGHT trial. It compares survival among adults with metastatic colorectal cancer who began trifluridine-tipiracil plus bevacizumab or trifluridine-tipiracil alone after p…

Nutrient Profile and Muscle Protein Synthesis in Response to Corn Bread Made From Refined Versus Whole Grain Maize Flour

The purpose of the study is to quantify and compare the serum nutrient and hormonal profile, and muscle protein synthesis rates, in response to consuming isonitrogenous amounts of a traditional East African meal, mung bean stew with a traditional African corn bread made from t…

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase II trial studies the side effects of bevacizumab and anetumab ravtansine or paclitaxel in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that does not respond to treatment (refractory). Bevacizumab is a monoclonal antibody that may inte…

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to anti-PD-1 inhibition in patients with detectable cir…

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in…

Study of Lung Proteins in Patients With Pneumonia

This study will examine the different types of proteins present in the lungs of patients with pneumonia to explore the causes of different types of the disease. Pneumonia is a condition that causes lung inflammation AND is often caused by an infection. It is usually diagnosed …

In Vitro Assessment of Chemically Modified Probiotic Bacteria as Receptor-Mimic Decoys for Cholera Toxin B Subunit

Gastrointestinal infections remain a major cause of morbidity and mortality worldwide. Conventional antibiotic treatment can be ineffective or inappropriate in some settings, particularly in the context of increasing antimicrobi-al resistance. In many enteric infections, an ea…

A StayGold-based calcium ion indicator

Genetically encoded calcium ion (Ca2+) indicators (GECIs) enable visualization of Ca2+ dynamics in living systems but often suffer from limited photostability during prolonged imaging. The recent discovery of StayGold, a green fluorescent protein (FP) with exceptional brightne…

The immunogenic 33-mer gliadin peptide attenuates flagellin-induced TLR5/NF-κB signaling

Wheat gluten is the main trigger of gluten-related disorders such as celiac disease, in which the proteolysis-resistant, 33-mer peptide is a key immunodominant factor. It has been reported that the 33-mer forms oligomers and thin-plate superstructures that accumulate in the Ca…

A monoallelic immunopeptidome atlas of 10 prevalent canine DLA-88 alleles

Characterization of naturally processed MHC class I (MHC-I)-bound peptides is essential for defining allele-specific peptide-binding features and understanding the functional consequences of MHC-I polymorphism. However, immunopeptidome analyses of dog leukocyte antigen (DLA) c…

A peptidomimetic inhibitor blocks Vibrio cholerae adhesin FrhA

Cholera is a diarrheal disease resulting from colonization of the small intestine by the Gram-negative bacterium Vibrio cholerae. The peptide-binding domain (PBD) of the adhesion protein FrhA is critical for V. cholerae intestinal colonization and biofilm formation. In a progr…

Lateral opening site of human oligopeptide transporter 2 plays a key role in the interaction with polymyxins

Multidrug-resistant (MDR) Gram-negative bacteria pose a critical global health threat, while polymyxins remain a last-line therapy. However, their clinical use is limited by nephrotoxicity. Human oligopeptide transporter 2 (hPepT2) is a membrane transporter mediating the reabs…

PeTFlow: Flow-Matching Based All-Atom Peptide Design through Side-Chain State Tokenization

Peptide offers a powerful modality for targeting protein-protein interfaces, yet their computational design remains challenging because sequence identity, backbone geometry and side-chain packing must be optimized simultaneously within a three-dimensional pocket constrained en…

Impact of Prolonged Obesity Across the Lifecourse on Myocardial Stress and Injury in Older Age: Birth Cohort Study

Background: The consequences of prolonged exposure to obesity on biomarkers of myocardial stress and injury remain unclear. We examined associations of duration and cumulative severity of obesity from childhood to later adulthood with concentrations of N-terminal pro-B-type na…

Human Intestinal Absorption Revisited: The 1998 Descriptors Survive, and the Method Extends to Permeability

In 1998 we predicted percent human intestinal absorption for 86 drug and drug-like compounds from six molecular descriptors chosen by a genetic algorithm and a small neural network. That result rested on one division of the compounds into training, cross-validation and externa…

A Hypothalamic Pathway for Energy Conservation

Many animals utilize a survival strategy of hypothermia, inactivity, and a dramatic decrease in their energy metabolism when faced with a shortfall in energy supplies. Mice, for example, show daily torpor that may last several hours to bridge the lack of energy availability in…

A gut-brain microbial sensing pathway mediates host defense and bacterial clearance

The digestive tract is a major site of nutrient absorption. It also harbors the densest microbial communities in our body. It is well known that the brain perceives ingested nutrient information through the intestinal epithelium enteroendocrine cell (EEC)-vagal pathway. Little…

Comparative Analysis of SCUBE-1, SIRI, NLR, and PLR as Predictors of 28-Day Mortality in Patients with Sepsis : A Cross- Sectional Study

Abstract Background: Sepsis is a life-threatening condition characterized by dysregulated host response to infection. Reliable prognostic biomarkers are needed for early risk stratification. This study evaluated SCUBE-1 (Signal Peptide-CUB-EGF-Like Domain-Containing Protein-1)…

Design and characterization of peptide-responsive biosensors

Gram-positive bacteria use secreted peptides and peptide-responsive transcription factors for quorum sensing. Here, we demonstrate that intracellular expression of these peptide effectors with their cognate transcription factors leads to regulation of gene expression in both i…

Tight junction suppression by candidalysin promotes gut-to-blood dissemination of Candida albicans

Addition of Unstructured Proline/Alanine/Serine (PAS) Tails to Folded Proteins Induces Chain Ejection Model Ionization in Native ESI-MS

Nationwide Outcomes and Predictors of Mortality After Left Ventricular Assist Device Implantation in Korea : Insights From the Korean Registry for Mechanically Assisted Circulatory Support

MAFLD and impaired bone formation in children: association with reduced serum LCAT

Preliminary Real-World Evidence of Clinical and Echocardiographic Changes After Vutrisiran Initiation in Patients With Variant Transthyretin Amyloid Cardiomyopathy in Non-Endemic Regions : A Single-Center Observational Study

Native Spleen T1 Mapping for the Assessment of Hepatic Congestion in Children With Congenital Heart Disease

Development and Internal Validation of D-DASH : A Prediction Model for Eating Difficulty at Discharge in Acute Heart Failure

Safety and Efficacy of Ponatinib for Pulmonary Tumor Thrombotic Microangiopathy

Reimagining the Wolff-Kishner Reduction: Light-Driven Carbonyl Deoxygenation without Strong Base

Effects of Tafamidis on Left Ventricular Strain in Patients With Wild-Type Transthyretin Cardiac Amyloidosis With and Without Diabetes Mellitus

From passive sealing to active microenvironment remodeling: design strategies, biological effects, and translational challenges of multifunctional hydrogels for postoperative pancreatic fistula prevention

Small cell transformation during acquired resistance to zongertinib in HER2-mutant non-small cell lung cancer: a case report

Nutritional Therapy for Acute Heart Failure Patients Admitted to the Cardiovascular Intensive Care Unit and Its Impact on the Nutritional Status at Discharge

Metabolic dysfunction-associated fatty liver disease: redefining the conceptual framework from nomenclature to emerging therapeutic paradigms

Reverse vaccinology and immunoinformatics-driven design of a multiepitope vaccine candidate against Renibacterium salmoninarum

Chitosan in regenerative medicine: a translational perspective on biomaterial design

Biliary microbiota and metabolic reprogramming in gallstone-associated gallbladder cancer: evidence from bile, stones, mucosa and tumor tissue

Therapeutic efficacy of recombinant human brain natriuretic peptide in elderly chronic heart failure patients: associations with changes in PⅢNP and suPAR levels

Case Report: Pallister-Hall syndrome diagnosed in adulthood during evaluation of recurrent hypoglycemia

Proteomic and Functional Profiling of Trichoderma reesei, Pichia guilliermondii, and Hericium erinaceus

Impact of Nutritional Risk on Long-Term Prognosis in Older Patients With Stage B Heart Failure : A PAPRIKA-HF Registry Subanalysis

Immunomodulatory Effects of Galleria mellonella and Alphitobius diaperinus Protein Digestates Generated Using a Modified INFOGEST Protocol – In Vitro and In Silico Evidence

Omentin-1 and cardiovascular disease: a comprehensive review from molecular mechanisms to clinical translation

Design and characterization of peptide-responsive biosensors

Gram-positive bacteria use secreted peptides and peptide-responsive transcription factors for quorum sensing. Here, we demonstrate that intracellular expression of these peptide effectors with their cognate transcription factors leads to regulation of gene expression in both i…

Discovery of sunflower-derived umami peptides via machine learning and molecular dynamics simulation of their interactions with the T1R1/T1R3 receptor

Type 2 diabetes-associated gut microbial composition and short chain fatty acids differ across the epidemiologic transition in African origin populations

Mechanism for Aromatic Nitration Catalyzed by Cytochrome P450 Enzymes from Rufomycin Biosynthesis

Insulin signaling in PCOS/PMOS: molecular insights and clinical implications

The mechanistic role of adipokine imbalance in airway inflammation, hyperresponsiveness, and remodeling in obesity-related asthma

From PCOS to PMOS: reframing the clinical pathway around insulin sensitivity and weight-neutral metabolic risk

Baseline BMI and weight change in dilated cardiomyopathy: associations with LVEF, BNP, and NYHA class

Decongested 2D IR Spectra Reveal N‑Terminal Helices in Amyloid Oligomers Associated with Type 2 Diabetes

NT-proBNP–echocardiographic discordance in type 2 diabetes: links with adiposity and left atrioventricular coupling

Aqueous-Phase Peptide Synthesis via Stepwise Amino Acid Elongation Catalyzed by Aqualigase

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 October 2026

CVMP opinions on veterinary medicinal productsThe Committee adopted a positive opinion, in exceptional circumstances, for a marketing authorisation for Bovilis Lumpyvax (lumpy…

Bio-Techne opens GMP small molecule facility in Bristol, UK

Life science tools and diagnostics provider Bio-Techne Corporation has opened a new manufacturing facility in Bristol, UK, dedicated to GMP grade small molecules.

Clinical trial applications advice pilot becomes permanent

The Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which helps sponsors prepare clinical trial applications, will become a permanent initiative from January 2027…

CPHI 2026: Finding the right CDMO partner in an age of consolidation

Executives from companies such as Leo Pharma and Daiichi Sankyo debated outsourcing selections and whether size is better in manufacturing.

Podcast: Key takeaways from EASD 2026 on where GLP-1s are headed

Experts discuss the latest research released at EASD 2026 and what it could mean for the diabetes community.

CPHI 2026: Moderna builds on its COVID-era manufacturing lessons

The biotech’s VP of Drug Product Operations Michelle Rodriguez on how it works with CDMOs.

GLP-1RA non-responders: tackling a hidden challenge behind the obesity epidemic

Improving outcomes for patients classed as ‘non-responders’ to GLP-1RA drugs remains a key unmet need within the obesity space.

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October

At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities to manage the safety of medicines, including the assessment of safety…, Agenda Agenda of the PRAC meeting 28 September - 1 October 2026Draft Reference Number: EMA/PRAC/204838/…

Magazine: Keep it cool

In this issue: Key themes of CPHI 2026, the GLP-1 manufacturing shift, cold chain logistics, and more.

FDA — Supplement approved · Labeling: EXENATIDE SYNTHETIC (AMNEAL)

Active ingredient(s): EXENATIDE SYNTHETIC. Marketed as EXENATIDE SYNTHETIC. Application ANDA206697.

FDA — Supplement approved · Labeling: EXENATIDE SYNTHETIC (AMNEAL)

Active ingredient(s): EXENATIDE SYNTHETIC. Marketed as EXENATIDE SYNTHETIC. Application ANDA206697.

FDA — Supplement approved · Labeling: EXENATIDE SYNTHETIC (AMNEAL)

Active ingredient(s): EXENATIDE SYNTHETIC. Marketed as EXENATIDE SYNTHETIC. Application ANDA206697.

Advice on ‘end-of-year’ submission dates for type I variations in 2026

Marketing authorisation holders wishing to receive an outcome in 2026 should submit type IA annual updates, individual type IA and type IAIN variations, and super-groupings…

EMA Management Board: highlights of September 2026 meeting

Mid-year report 2026 from the Executive DirectorEMA presented results and achievements of its operations for the first half of 2026 to the Management Board. Between January and…

Global regulators call for advancing alternatives to animal testing across the medicine lifecycle

EMA has endorsed a joint statement from the International Coalition of Medicines Regulatory Authorities (ICMRA) calling on medicine developers, manufacturers, regulators and…

Executive Director speech at EMA women’s health multi-stakeholder workshop

Amsterdam, 28 September 2026Check against delivery (The published text is based on the prepared speech. Minor differences may have occurred during delivery)Good morning,…

EASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis

Tirzepatide delivers stronger real-world glycaemic and weight-loss outcomes than oral and injectable semaglutide in type 2 diabetes.

Leading CDMO to attend CPHI Milan 2026 in Italy